Longterm effects of chronic cannabis consumption;Langfristige folgen des chronischen cannabiskonsums

Sucht

Volumn 50, Issue 5, 2004, Pages 309-319

  Schneider, Miriam ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

Addiction; Cannabinoids; Cognitive impairments; Puberty; Schizophrenia

Indexed keywords

CANNABIS;

ADOLESCENT; AGE DISTRIBUTION; CANNABIS ADDICTION; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DOPAMINERGIC SYSTEM; GERMANY; HIGH RISK POPULATION; HUMAN; MEDICAL LITERATURE; NERVE CELL; NONHUMAN; PUBERTY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 8444226402     PISSN: 09395911     EISSN: None     Source Type: Journal    
DOI: 10.1463/2004.05.04     Document Type: Review

References (81)

1. Ameri, A. (1999) The effects of cannabinoids on the brain. Progress in Neurobiology 58, 315-348.
2. Andersen, S. L., Thompson, A. T., Rutstein, M., Hostetter, J. C. & Teicher, M. H. (2000) Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse 37, 167-169.
3. Andersen, S. L., Thompson, A. P., Krenzel, E. & Teicher, M. H. (2002) Pubertal changes in gonadal hormones do not underlie adolescent dopamine receptor overproduction. Psychoneuroendocrinology 27, 683-691.
4. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A. & Moffitt, T. E. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212-1213.
5. Arseneault, L., Cannon, M., Witton, J. & Murray, R. M. (2004) Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110-117.
6. Barch, D. M., Sheline, Y. I., Csernansky, J. G. & Snyder, A. Z. (2003) Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biological Psychiatry 53, 376-384.
7. Braff, D. L., Geyer, M. A., Light, G. A., Sprock, J., Perry, W., Cadenhead, K. S. & Swerdlow, N. R. (2001) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophrenia Research 49, 171-178.
8. Braff, D. L., Geyer, M. A. & Swerdlow, N. R. (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156, 234-258.
9. Braff, D. L., Grillon, C. & Geyer, M. A. (1992) Gating and habituation of the startle reflex in schizophrenic patients. Archives of General Psychiatry 49, 206-215.
10. Carlsson, A., Waters, N. & Carlsson, M. L. (1999) Neurotransmitter interactions in schizophrenia - therapeutic implications. Biological Psychiatry 46, 1388-1395.
11. Caspari, D. (1999) Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience 249, 45-49.
12. Chambers, R. A., Taylor, J. R. & Potenza, M. N. (2003) Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. American Journal of Psychiatry 160, 1041-1052.
13. Chaperon, F. & Thiebot, M. (1999) Behavioral effects of cannabinoid agents in animals. Critical Reviews in Neurobiology 13, 243-281.
14. Chen, J., Paredes, W., Lowinson, J. H. & Gardner, E. L. (1990) Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. European Journal of Pharmacology 190, 259-262.
15. Childers, S. R. & Breivogel, C. S. (1998) Cannabis and endogenous cannabinoid systems. Drug and Alcohol Dependence 51, 173-187.
16. Coleman, M. J., Cook, S., Matthysse, S., Barnard, J., Lo, Y., Levy, D. L., Rubin, D. B. & Holzman, P. S. (2002) Spatial and object working memory impairments in schizophrenia patients: a Bayesian item-response theory analysis. Journal of Abnormal Psychology 111, 425-435.
17. Cook, S. A., Lowe, J. & Martin, B. R. (1998) CB1 receptor antagonist precipates withdrawl in mice exposed to D9-tetrahydrocannabinol. The Journal of Pharmacology and Experimental Therapeutics 285, 1150-1156.
18. Crespo-Facorro, B., Wiser, A. K., Andreasen, N. C., O'Leary, D. S., Watkins, G. L., Boles Ponto, L. L. & Hichwa, R. D. (2001) Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Human Brain Mapping 12, 219-231.
19. Crystal, J. D., Maxwell, K. W. & Hohmann, A. G. (2003) Cannabinoid modulation of sensitivity to time. Behavioural Brain Research 144, 57-66.
20. D'Souza, D. C., Abi-Saab, W., Madonick, S., Wray, Y., Forselius, K., MacDougall, L., Brush, L., Cassello, K. & Krystal, J. (2000) Cannabinoids and psychosis: Evidence from studies with i. v. THC in schizophrenic patients and controls (abstract). Schizophrenia Research 41, 33
21. De Bellis, M. D., Keshavan, M. S., Beers, S. R., Hall, J., Frustaci, K., Masalehdan, A., Noll, J. & Boring, A. M. (2001) Sex differences in brain maturation during childhood and adolescence. Cerebral Cortex 11, 552-557.
22. De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F. & Di, M., V. (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease. 2, 5
23. Dean, B., Sundram, S., Bradbury, R., Scarr, E. & Copolov, D. (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
24. Devane, W. A., Dysarz, F. A. I., Johnson, M. R., Melvin, L. S. & Howlett, A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34, 605-613.
25. Ehrenreich, H., Rinn, T., Kunter, H. J., Moeller, M. R., Poser, W., Schilling, L., Gigerenzer, G. & Hoehe, M. R. (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142, 295-301.
26. El-Gohary, M. & Eid, M. A. (2004) Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Human & Experimental Toxicology 23, 149-156.
27. Ellenbroek, B. A. & Cools, A. R. (2000) Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 11, 223-233.
28. Emrich, H. M., Leweke, F. M. & Schneider, U. (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology, Biochemistry and Behavior 56, 803-807.
29. Fergusson, D. M. & Norwood, L. J. (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95, 505-520.
30. French, E. D., Dillon, K. & Wu, X. (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8, 649-652.
31. Geyer, M. A., Krebs-Thomson, K., Braff, D. L. & Swerdlow, N. R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117-154.
32. Glass, M., Dragunow, M. & Faull, R. L. M. (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318.
33. Gomez, F., Houshyar, H. & Dallman, M. F. (2002) Marked regulatory shifts in gonadal, adrenal, and metabolic system responses to repeated restraint stress occur within a 3-week period in pubertal male rats. Endocrinology 143, 2852-2862.
34. Hall, W. (2001) Reducing the harms caused by cannabis use: the policy debate in Australia. Drug and Alcohol Dependence 62, 163-174.
35. Hall, W. & Solowij, N. (1998) Adverse effects of cannabis. Lancet 352, 1611-1616.
36. Hambrecht, M. & Häfner, H. (2000) Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. The Australian and New Zealand Journal of Psychiatry 34, 468-475.
37. Han, C. J. & Robinson, J. K. (2001) Cannabinoid modulation of time estimation in the rat. Behavioral Neuroscience 115, 243-246.
38. Heckers, S., Curran, T., Goff, D., Rauch, S. L., Fischman, A. J., Alpert, N. M. & Schacter, D. L. (2000) Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biological Psychiatry 48, 651-657.
39. Herkenham, M., Lynn, A. B., de Costa, B. R. & Richfield, E. K. (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research 547, 267-274.
40. Jentsch, J. D., Andrusiak, A., Tran, A., Bowers, M. B. & Roth, R. H. (1997) D9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16, 426-432.
41. Koch, M. (1999) The neurobiology of startle. Progress in Neurobiology 59, 107-128.
42. Koch, M. (2002) Animal models in schizophrenia research. Neuroforum 8, 236-244.
43. Kouri, E. M., Pope, H. G. & Lukas, S. E. (1999) Changes in aggressive behavior during withdrawl from long-term marijuana use. Psychopharmacology 143, 302-308.
44. Kumari, V., Soni, W., Mathew, V. M. & Sharma, T. (2000) Prepulse inhibition of the startle response in men with schizophrenia. Archives of General Psychiatry 57, 609-614.
45. Lamarque, S., Taghzouti, K. & Simon, H. (2001) Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41, 118-129.
46. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M. & Piomelli, D. (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
47. Leweke, F. M., Schneider, U., Thies, M., Munte, T. F. & Emrich, H. M. (1999) Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. 142, 230-235.
48. McDonald, J., Schleifer, L., Richards, J. B. & de Wit, H. (2003) Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28, 1356-1365.
49. Mechoulam, R. & Parker, L. (2003) Cannabis and alcohol - a close friendship. Trends in Pharmacological Sciences 24, 266-268.
50. Meincke, U., Gouzoulis-Mayfrank, E. & Sass, H. (2001) The startle reflex in schizophrenia research. Nervenarzt 72, 844-852.
51. Menhiratta, S. S., Wig, N. N. & Verma, S. K. (1978) Some psychological correlates of long-term heavy cannabis users. British Journal of Psychiatry 132, 482-486.
52. Morral, A. R., McCafrey, D. F. & Paddock, S. M. (2002) Evidence does not favor marijuana gateway effects over a common-factor interpretation of drug use initiation: responses to Anthony, Kenkel & Mathios and Lynskey. Addiction 97, 1509-1510.
53. Park, B., McPartland, J. M. & Glass, M. (2004) Cannabis, cannabinoids and reproduction. Prostaglandins, Leukotrienes and Essential Fatty Acids. 70, 189-197.
54. Pellis, S. M. & Pellis, V. C. (1997) The prejuvenile onset of play fighting in laboratory rats (Rattus norvegicus). Developmental Psychobiology 31, 193-205.
55. Pellis, S. M., Pellis, V. C. & Wishaw, I. Q. (1992) The role of the cortex in play fighting by rats: developmental and evolutionary implications. Brain, Behavior and Evolution 39, 270-284.
56. Perkonigg, A., Lieb, R., Hofler, M., Schuster, P., Sonntag, H. & Wittchen, H. U. (1999) Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents. Addiction 94, 1663-1678.
57. Pistis, M., Porcu, G., Melis, M., Diana, M. & Luigi, G. G. (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. European Journal of Neuroscience 14, 96-102.
58. Pistis, M., Ferraro, L., Pira, L., Flore, G., Tanganelli, S., Gessa, G. L. & Devoto, P. (2002) Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Research 948, 155-158.
59. Pistis, M., Perra, S., Pillolla, G., Melis, M., Muntoni, A. L. & Gessa, G. L. (2004) Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biological Psychiatry 56, 86-94.
60. Pope, H. G., Gruber, A. J., Hudson, J. I., Cohane, G., Huestis, M. A. & Yurgelun-Todd, D. (2003) Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug and Alcohol Dependence 69, 303-310.
61. Rodriguez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F. & Weiss, F. (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawl. Science 276, 2050-2054.
62. Rodriguez de Fonseca, F., Ramos, J. A., Bonnin, A. & Fernandez-Ruiz, J. J. (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4, 135-138.
63. Santucci, V., Storme, J. J., Soubrie, P. & Le Fur, G. (1996) Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Science 58, L103-L110
64. Schneider, M. & Koch, M. (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769.
65. Schneider, U., Leweke, F. M., Mueller-Vahl, K. R. & Emrich, H. M. (1998) Cannabinoid/anandamide system and Schizophrenia: Is there evidence for association? Pharmacopsychiatry 31, 110-113.
66. Skosnik, P. D., Spatz-Glenn, L. & Park, S. (2001) Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 48, 83-92.
67. Spear, L. P. (2000) The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews 24, 417-463.
68. Stiglick, A. & Kalant, H. (1985) Residual effects of chronic cannabis treatment on behavior in mature rats. Psychopharmacology 85, 436-439.
69. Swerdlow, N. R., Braff, D. L., Taaid, N. & Geyer, M. A. (1994) Assesing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Archives of General Psychiatry 51, 139-154.
70. Swerdlow, N. R., Braff, D. L. & Geyer, M. A. (2000) Animal models of deficient sensorimotor gating: what we know, what we think, and what we know to hope soon. Behavioural Pharmacology 11, 185-204.
71. Taylor, D. R. & Hall, W. (2003) Respiratory health effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand. International Medicine Journal 33, 310-313.
72. van der Stelt, M. & Di Marzo, V. (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480, 133-150.
73. van Os, J., Bak, M., Hanssen, M., Bijl, R. V., de Graaf, R. & Verdoux, H. (2002) Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 156, 319-327.
74. Voruganti, L. N., Slomka, P., Zabel, P., Mattar, A. & Awad, A.G. (2001) Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research 107, 173-177.
75. Watson, S. J., Benson, J. A. J. & Joy, J. E. (2000) Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Archives of General Psychiatry 57, 547-552.
76. Weike, A. I., Bauer, U. & Hamm, A. O. (2000) Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biological Psychiatry 47, 61-70.
77. Wenger, T., Gerendai, I., Fezza, R, Gonzalez, S., Bisogno, T., Fernandez-Ruiz, J. & Di Marzo, V. (2002) The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Science 70, 1407-1414.
78. Wilson, W., Mathew, R., Turkington, T., Hawk, T., Coleman, R. E. & Provenzale, J. (2000) Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. Journal of Addictive Diseases 19, 1-22.
79. Wu, X. & French, E. D. (2000) Effects of chronic delta9- tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39, 391-398.
80. Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. & Lewis, G. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 325, 1199
81. Zavitsanou, K., Garrick, T. & Huang, X. F. (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 28, 355-360.